Biosynex: acquisition of Qualigen in the United States
Initially 100% owned by Qualigen Therapeutics - which wished to refocus on its therapeutic activities - Qualigen Inc develops, produces and markets a Fastpack immunoanalysis platform, marketed in Europe and the United States.
Fastpack is used in urologists' offices and men's health centers in the USA (more than 300 active customers).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction